Table 2. Compound Associated with Casein or Whey Protein (nmol/mg Protein and Percent Association Based on Whole Milk).

compound	nominal conc. of whole milka (actual) nM	nmol/mg casein proteinb	nmol/mg whey proteinc	conc. in casein/conc. in whey protein	mean % casein association based on whole milkd	mean % whey association based on whole milkd
GLY	20 (22)	0.08	0.15	0.53	7.92	3.68
	200 (217)	0.71	1.40	0.51
	2000 (2059)	6.52	14.09	0.46
IMI	20 (20)	0.21	0.11	1.91	15.43	3.19
	200 (201)	2.20	1.13	1.95
	2000 (2066)	22.33	12.29	1.82
BPA	20 (22)	0.44	0.23	1.91	45.76	6.68
	200 (216)	4.54	2.25	2.02
	2000 (1992)	42.43	20.88	2.03
E1	20 (20)	0.21	0.10	2.10	17.86	3.52
	200 (200)	1.66	0.96	1.73
	2000 (1796)	15.89	8.70	1.83
3-MeSO2-PCB-101	20 (24)	0.06	0.04	1.50	4.25	0.99
	100 (70)	0.18	0.12	1.50
	500(628)	1.60	1.08	1.48
TCC	20 (19)	0.05	0.10	0.50	5.92	3.62
	200 (193)	0.54	0.95	0.57
	2000 (1938)	5.68	9.72	0.58
2-OH-1378-TCDD	20 (22)	0.16	0.64	0.25	17.85	16.79
	100 (107)	0.77	3.26	0.24
	500 (556)	4.71	16.16	0.29
PCB-118	50 (60)	0.07	<LOQe		3.42	0.70
	200 (221)	0.35	0.24	1.46
	2000 (2203)	2.90	2.37	1.22
β-HBCD	200 (229)	0.38	<LOQe		2.95	0.59
	500(656)	1.09	0.59	1.85
	2000 (2067)	3.21	2.11	1.52
1278-TCDD	20 (27)	0.11	0.06	1.83	4.14	1.29
	200 (184)	0.46	0.34	1.35
	2000 (1784)	5.07	3.58	1.42
TBBPA	20	0.27	0.79	0.34	18.01	22.96
	200 (234)	3.53	9.36	0.38
	2000 (1815)	21.63	76.47	0.28
BDE-99	20 (20)	0.12	0.03	4.0	6.66	1.20
	200 (178)	1.05	0.38	2.76f
	2000 (1890)	18.33	3.35	5.47

^aSA of some compounds required different doses, as indicated by bold text. Each fortified level contains three replicates.

^bThese data were derived from phase 2 data and have whey associated drug subtracted, using “0% moisture curd” as described in text.

^cThese data were derived from phase 3 data as described in the text.

^dMean of all doses.

^eLess than limit of quantitation (<LOQ). LOQ for PCB-118 is 1.92 nmol/L and for β-HBCD was 9.87 nmol/L.

^fInconsistent with other doses. No explanation.